China
CARBOGEN AMCIS manufacturing license advances services in China
April 23, 2025Manufacturing Services, Manufacturing and Production Carbogen Amcis, China, Corporate, Drug Manufacturing License (DML), Shanghai, manufacturing
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has been successfully granted Drug Manufacturing …
NDA in China receives priority review status for lung cancer treatment
January 3, 2025Research and Development China, China National Medical products Administration, HUTCHMED, NDA, Oncology, epidermal growth factor receptor, non-small cell lung cancer, priority review
HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority review for a new drug …
China’s NMPA accepts Everest Medicines’ Nefecon supplementary application
July 18, 2024Medical Communications China, Everest Medicines, NMPA, Nephrology
Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission of a supplemental New Drug …
AstraZeneca and Sanofi’s Beyfortus approved in China
January 2, 2024Research and Development AstraZeneca, Beyfortus, China, Immunology, Sanofi
AstraZeneca and Sanofi have announced that Beyfortus (nirsevimab) has been approved in China for the prevention of respiratory syncytial virus …
First patient enrolled in Boan Biotech’s phase 3 trial for Nivolumab in China
October 30, 2023Research and Development Boan Biotech, China, Oncology, clinical trial, nivolumab
Boan Biotech has announced that the first patient has been enrolled in its phase 3 trial of its Nivolumab injection …
AstraZeneca’s Calquence approved in China for chronic lymphocytic leukaemia treatment
September 4, 2023Medical Communications AstraZeneca, CLL, China, Oncology, SLL
AstraZeneca has announced that Calquence (acalabrutinib) has been approved in China for the treatment of adult patients with chronic lymphocytic …
AstraZeneca’s Forxiga approved in China for chronic heart failure treatment
August 18, 2023Medical Communications AstraZeneca, Cardiology, China, cardiovascular, heart failure
AstraZeneca has announced that Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular death, hospitalisation for …
Jacobio Pharma receives CDE approval for pancreatic cancer study in China
July 5, 2023Medical Communications CDE, China, Jacobio Pharma, Oncology, Pancreatic cancer, clinical trial
Jacobio Pharma has announced that its novel KRAS G12C inhibitor glecirasib’s pivotal study for pancreatic cancer has been approved by …
AstraZeneca’s Xigduo XR approved in China for adults with type-2 diabetes
June 27, 2023Medical Communications AstraZeneca, China, Diabetes, Xigduo XR, diabetes
AstraZeneca has announced that its Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has now been approved …
China rejects a second WHO probe into COVID outbreak origin
July 22, 2021COVID-19, China
China has rejected WHO plans for a second investigation into the origin of the coronavirus pandemic, which includes the hypothesis …
Positive phase III results achieved for dialysis drug in China
April 30, 2021Medical Communications China, Kideny disease
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the …
UAE rolls out Sinopharm COVID-19 vaccine amid conflicting reports of efficacy
December 15, 2020Manufacturing and Production, Research and Development COVID-19, China, Sinopharm, UAE, coronavirus
The United Arab Emirates has begun rolling out Sinopharm’s COVID-19 vaccine in its capital Abu Dhabi, despite claims that numerous …
China approves Takeda’s Takhzyro to prevent hereditary angioedema attacks in patients over 12
December 8, 2020Manufacturing and Production, Sales and Marketing China, Takeda
China’s National Medical Products Administration (NMPA) has given approval in the country for Takeda’s Takhzyro (lanadelumab), in a subcutaneous injection …
China approves Astellas’ Xtandi in non-metastatic castration-resistant prostate cancer
November 6, 2020Medical Communications, Sales and Marketing Astellas, China, NMPA, Xtandi
China’s drug regulator, the National Medical Products Administration (NMPA), has given the green light to Astellas to market Xtandi (enzalutamide …
Study that alleges COVID-19 was made in a Chinese lab originated from non-profits linked to ex-Trump advisor Steve Bannon
September 16, 2020Research and Development China, Donald Trump, Steve Bannon, Wuhan, coronavirus
A new study that alleges COVID-19 was created in a Chinese lab was published by two non-profits that are linked …
